精品国产_亚洲人成在线高清,国产精品成人久久久久,国语自产偷拍精品视频偷拍

立即打開
Amgen's DMab scores in trials

Amgen's DMab scores in trials

2009年07月10日

????For the biotech, a new drug for bone cancer and osteoporosis could mean a big boost in revenue.

????By Alyssa Abkowitz

????An Amgen trial drug -- called denosumab -- reached a new milestone on July 7 when the biotechnology company announced results from the latest clinical trial of the drug for bone cancer. The trial of more than 2,000 patients showed DMab -- which works to slow bone destruction, a primary concern for people with advanced cancer and the cause of a myriad of complications, including fractures -- delayed the time it took for damage to occur when compared to rival drug Zometa, which is made by Novartis. Amgen has already submitted DMab to the Food and Drug Administration as a treatment for osteoporosis.

????"We're very, very excited about it," Amgen CEO Kevin Sharer told Fortune. "This has been a drug we've worked on for 15 years. We did the fundamental biology and invested over $1 billion. I bet my job on it."

????Yesterday, the day after the announcement, Amgen's stock surged 14% -- the most in four years. Analysts had a field day in their notes, with some increasing Amgen's share price expectations to more than $70 and others upping annual revenue estimates for DMab to as high as $3 billion.

????Steve Yoo, an analyst at health care investment bank Leerink Swann, estimated in a note that U.S. sales of DMab as a treatment for bone cancer could hit $558 million by 2012. And U.S. sales of the drug as an osteoporosis therapy could total more than $2 billion in the same period, for an overall DMab revenue of more than $3 billion by Yoo's calculations.

????By comparison, Zometa brought in $1.4 billion in sales last year. Yoo noted that the cost of DMab will likely be higher than Zometa, but warned that pricing it too high could limit prescriptions of the drug as an osteoporosis treatment.

????DMab is a biologic -- a medicine made from living organisms -- and works by blocking the activity of the protein that regulates the cells responsible for breaking down bone, making it valuable as an osteoporosis therapy. When used as a bone cancer treatment, it targets metastases that are extremely prevalent with certain types of advanced cancer, reaching incident rates of nearly 75% in breast and prostate cancer patients, according to Amgen (AMGN, Fortune 500).

????The biotech expects an FDA decision on DMab as an osteoporosis therapy by Oct. 19. Yoo says there's no timeline yet on when the drug will be submitted to the agency for approval as a bone cancer treatment. But whenever the decisions arrive, approval of DMab for both uses would mean a big boost for Amgen. "I think it'll really be important for patients," Sharer told Fortune. "So it's very, very important to us."

  • 熱讀文章
  • 熱門視頻
活動
掃碼打開財富Plus App

            主站蜘蛛池模板: 高密市| 临漳县| 金坛市| 华亭县| 蒙阴县| 平罗县| 吴桥县| 张北县| 武邑县| 崇仁县| 和静县| 滁州市| 迁西县| 聊城市| 新宾| 桦南县| 清远市| 北辰区| 鄂伦春自治旗| 临邑县| 婺源县| 休宁县| 张北县| 鄯善县| 泸定县| 禹州市| 谢通门县| 重庆市| 东宁县| 丽江市| 镇江市| 吉木乃县| 黄浦区| 枣庄市| 兴海县| 绥阳县| 邻水| 韶山市| 茂名市| 湘阴县| 分宜县|